REACH Interview Series: Ron Carucci

The Reach Interview Series is an informal dialogue between me and respected thought leaders around the theme of my new book,  Reach: A New Strategy to Help You Step Outside Your Comfort Zone, Rise to the Challenge and Build Confidence.

As an experienced consultant to CEO’s and executives of some of the biggest companies in the world, Ron Carucci is deeply experienced in helping others stretch outside their comfort zones. But in this personal interview, Ron discloses some of the comfort zone challenges he has experienced in his life and how he has overcome them.


AVAILABLE NOW

Reach A New Strategy to Help You Step Outside Your Comfort Zone 

Prescriptive and based not only on my groundbreaking research but on my own quest to get out of my comfort zone, Reach will help you take the thing you are most afraid of doing and make it a proud part of your personal repertoire.

Learn More

Related Posts

Reinventing the Feedback Sandwich – 5 Different Ways

Reinventing the Feedback Sandwich – 5 Different Ways

One of the most challenging parts of becoming a manager or a leader is delivering feedback.

Read More

REACH Interview Series: Scott Sonenshein

REACH Interview Series: Scott Sonenshein

The Reach Interview Series is an informal dialogue between me and respected thought leaders around the theme of my new book,  Reach: A New Strategy to Help You Step Outside Your Comfort Zone, Rise to the Challenge and Build Confidence. 

Read More

2017: The Year to Break Out of Your Comfort Zone

2017: The Year to Break Out of Your Comfort Zone

You’d like to contribute to discussions at your company, but you can never get a word in edgewise. 

Read More

Building Relationships vs. Getting Down to Business

Building Relationships vs. Getting Down to Business

Xavier Frei wanted to get down to business. A Zurich-born manager with 10 years’ experience working in Germany and Switzerland, Xavier had just landed a few days ago in Monterrey, Mexico, at a small pharmaceutical company that was recently purchased by Xavier’s company, a major European pharmaceutical firm.

Read More